Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a
kinase downstream of the B-cell receptor that is critical for B-cell survival and proliferation. In …

Ibrutinib (Imbruvica™) is a small molecule, first-in-class, once-daily, orally available, Bruton's
tyrosine kinase inhibitor that is under development for the treatment of B cell malignancies …

Whole genome sequencing has revealed activating somatic mutations in MYD88 (L265P)
and CXCR4 in Waldenström macroglobulinemia (WM). CXCR4 somatic mutations in WM …

Chronic lymphocytic leukemia (CLL) is characterized by immune dysregulation, often
including hypogammaglobulinemia, which contributes to a high rate of infections and …

CXCR4 WHIM somatic mutations are common Waldenstrom's Macroglobulinemia (WM), and
are associated with clinical resistance to ibrutinib. We engineered WM cells to express the …

The CXC chemokine receptor type 4 (CXCR4) plays a crucial role in modulating cell
trafficking in hematopoietic stem cells and clonal B cells. We screened 418 patients with B …

Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia
(CLL), including those with an unfavorable cytogenetic profile. However, patients develop …

Bortezomib frequently produces severe treatment-related peripheral neuropathy (PN) in
Waldenström's macroglobulinemia (WM). Carfilzomib is a neuropathy-sparing proteasome …

The therapy of relapsed chronic lymphocytic leukemia (CLL) has changed dramatically in
the past year with the regulatory approval of idelalisib and ibrutinib, with other therapeutic …

Waldenström macroglobulinaemia (WM) is a rare and incurable lymphoma. Given that the
survival of WM patients can be prolonged, our objective was to describe trends in overall …